NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer

By afschroeder • June 27, 2025

Braunstein LZ, Mitchell MP, Bandos H, Sikov WM, Khan AJ, Chen PY, Ganz PA, Jagsi R, White JR, Cecchini RS, Kang H, Puhalla SL, Bolton KL, Connolly EP, Stringer-Reasor EM, Gergelis KR, Julian TB, Mamounas EP, Wolmark N. NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer. Future Oncol. 2025 Jun 26:1-9. doi: 10.1080/14796694.2025.2511586. Epub ahead of print. PMID: 40574381.

Tags: adjuvant breast radiotherapy, Breast cancer treatment, Breast-conservation therapy, Hematology/Oncology, HER2-positive breast cancer, HER2-targeted therapy, oncological outcomes, Publications, quality of life outcomes

Finetuning Type I Interferon Signaling to Enhance T Cell Immunity in HIV Infection

Mu W, Kedia N, Zhen A. Finetuning Type I Interferon Signaling to Enhance T Cell Immunity in HIV Infection. Viruses. 2025 May 29;17(6):774. doi: 10.3390/v17060774.[...]

Unbridled Enthusiasm for Neoadjuvant Chemoimmunotherapy followed by Surgery for Locally Advanced Non-Small Cell Lung Cancer

Moghanaki D, Cameron EA, Garon EB. Unbridled Enthusiasm for Neoadjuvant Chemoimmunotherapy followed by Surgery for Locally Advanced Non-Small Cell Lung Cancer. Lung Cancer. 2025 Jun[...]

Q-TWiST Analysis to Assess Benefit-Risk of Sacituzumab Govitecan in Previously Treated Patients With Metastatic Triple-Negative Breast Cancer

Bardia A, Rugo HS, Sedrak MS, Loibl S, Tolaney SM, Punie K, Hurvitz SA, Kalinsky KM, Cortés J, O'Shaughnessy JA, Dieras V, Piccart-Gebhart MJ, Dasgupta[...]